{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":19,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":19,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"b648535b812a","filters":{"venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector"}},"results":[{"id":"W3121226665","doi":"10.1057/jgm.2010.14","title":"Ever-Greening: A Status Check in Selected Countries","year":2010,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":16,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Mylan","keywords":"Business; Greening; Product (mathematics); Index (typography); Developing country; Duration (music); Generic drug; International trade; Development economics; International economics; Economics; Economic growth; Medicine; Political science","authors":[{"name":"Sandeep Rathod","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06957175371250879,"gpt":0.2992529218035228,"spread":0.229681168091014,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003120998,0.0001958582,0.0003825734,0.004377629,0.0008325033,0.002588872,0.0004433515,0.0007220773,0.00350136],"category_scores_gemma":[0.006306943,0.0002020476,0.0004303242,0.007928319,0.0008029894,0.002137243,0.001329908,0.0006697288,0.0004835991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001067379,"about_ca_system_score_gemma":0.001486495,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01326854,"about_ca_topic_score_gemma":0.01638399,"domain_scores_codex":[0.9989514,0.0001860172,0.0001890686,0.0001141785,0.0002824657,0.0002768228],"domain_scores_gemma":[0.9873704,0.001771627,0.005317786,0.000596523,0.003722778,0.001220987],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001012958,0.0001515093,0.8240218,0.001253698,0.0001642856,0.001656788,0.003666664,0.0005229881,0.001480031,0.00433056,0.02565835,0.1360805],"study_design_scores_gemma":[0.00003299221,0.0002848932,0.9384708,0.0004200011,0.00008726943,0.0007976358,0.006082499,0.0001877556,0.0008074649,0.0003573983,0.05244096,0.00003031184],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9053883,0.02463063,0.000474353,0.0131329,0.000478117,0.0001204672,0.007346468,0.0001572948,0.04827148],"genre_scores_gemma":[0.9849029,0.007790472,0.0004130364,0.001480038,0.0001451357,0.00003132928,0.002114183,0.00003125813,0.003091595],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01326854,"threshold_uncertainty_score":0.02638263,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2051735118","doi":"10.1177/1741134311408275","title":"The 2011 Canada-European Union Comprehensive Economic and Trade Agreement: an economic impact assessment of the EU’s proposed pharmaceutical intellectual property provisions","year":2011,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"European union; Intellectual property; Economic impact analysis; International trade; International economics; Business; Trade agreement; Economics; Political science; Free trade; Law","authors":[{"name":"Paul Grootendorst","is_ca":true},{"name":"Aidan Hollis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1723399961483894,"gpt":0.2933692034571246,"spread":0.1210292073087351,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023523,0.001334619,0.001120609,0.006944272,0.009925602,0.0177169,0.004695924,0.009250577,0.004213163],"category_scores_gemma":[0.05143496,0.001196344,0.00271998,0.007034364,0.005004542,0.002893229,0.004573389,0.00611505,0.0004890229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.1346158,"about_ca_system_score_gemma":0.2448309,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9298305,"about_ca_topic_score_gemma":0.9293284,"domain_scores_codex":[0.9390424,0.005029213,0.001235698,0.001485048,0.04278943,0.01041816],"domain_scores_gemma":[0.9691394,0.009198555,0.001949492,0.001316735,0.01621296,0.002182859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.001015362,0.0005515168,0.0218206,0.0004617196,0.0003417179,0.001191043,0.001506836,0.03600403,0.001523891,0.8148058,0.08667379,0.03410369],"study_design_scores_gemma":[0.001525512,0.001251937,0.2583572,0.001550094,0.001499826,0.000450082,0.007744982,0.04137018,0.009993841,0.05590194,0.61915,0.001204345],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.2645703,0.005287239,0.005181746,0.02987737,0.000615161,0.001860164,0.008562174,0.0002375928,0.6838083],"genre_scores_gemma":[0.8958971,0.003013733,0.01093833,0.01632292,0.0001605259,0.0009232517,0.004708783,0.00009706671,0.06793819],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1346158,"threshold_uncertainty_score":0.9767103,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139728736","doi":"10.1177/1741134312448062","title":"Deficiencies in generic product dossiers as submitted to the WHO Prequalification of Medicines Programme","year":2012,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Canada","funders":"","keywords":"Medicine; Product (mathematics); Malaria; Tuberculosis; Quality (philosophy); Pharmacy; Traditional medicine; Family medicine","authors":[{"name":"Wondiyfraw Z Worku","is_ca":false},{"name":"John Gordon","is_ca":true},{"name":"Matthias Stahl","is_ca":false},{"name":"Lembit Rägo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1585768476361802,"gpt":0.3848409297933217,"spread":0.2262640821571416,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04373801,0.0002917306,0.0005638822,0.005602458,0.0006084852,0.001687053,0.00124301,0.0008363887,0.00248944],"category_scores_gemma":[0.1131411,0.0003662223,0.0007023103,0.003687585,0.001145465,0.001254531,0.001496324,0.0006003,0.0006352633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002703156,"about_ca_system_score_gemma":0.002541197,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002716677,"about_ca_topic_score_gemma":0.002165412,"domain_scores_codex":[0.9416571,0.01858261,0.01410293,0.002936527,0.02143268,0.001288108],"domain_scores_gemma":[0.7945216,0.05926665,0.1001569,0.01602809,0.02846181,0.001564929],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001561847,0.0003170756,0.76279,0.001463973,0.0001871335,0.0006890749,0.004097251,0.001551284,0.008889442,0.001652045,0.002704302,0.2140965],"study_design_scores_gemma":[0.00009102438,0.0023354,0.9375222,0.000733209,0.0001794616,0.003109441,0.002350623,0.002060446,0.01548235,0.0008584929,0.03515503,0.0001223367],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736984,0.003494136,0.004455863,0.001241437,0.00008655602,0.0007782657,0.003424312,0.0001797369,0.01264133],"genre_scores_gemma":[0.9882491,0.0007977278,0.006276375,0.0006702081,0.00004975373,0.0001437841,0.002308314,0.00003806872,0.001466702],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04373801,"threshold_uncertainty_score":0.2313114,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2525448133","doi":"10.1177/1741134316669967","title":"A comparison of mechanisms for setting generic drug prices in Canada","year":2016,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto; University of Calgary","funders":"","keywords":"Reimbursement; Procurement; Benchmarking; Competition (biology); Business; Incentive; Discretion; Generic drug; Pharmacy; Public economics; Actuarial science; Drug; Industrial organization; Economics; Marketing; Microeconomics; Pharmacology; Medicine; Health care","authors":[{"name":"Aidan Hollis","is_ca":true},{"name":"Paul Grootendorst","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09433249734598782,"gpt":0.3147139386442177,"spread":0.2203814412982298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004443487,0.0004687765,0.0006799741,0.003755268,0.0039836,0.005381864,0.002450817,0.001161755,0.004944932],"category_scores_gemma":[0.01977403,0.0004717871,0.001040122,0.005991971,0.001583662,0.001277442,0.00158171,0.001172257,0.0002426397],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.164503,"about_ca_system_score_gemma":0.1278311,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9928654,"about_ca_topic_score_gemma":0.9941745,"domain_scores_codex":[0.9912854,0.001026091,0.0003868284,0.0004166191,0.004423127,0.002461951],"domain_scores_gemma":[0.9889801,0.002839873,0.0009695415,0.0003708961,0.005572585,0.001266995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","study_design_scores_codex":[0.002675022,0.0006044111,0.1730235,0.002615871,0.0009103204,0.001170696,0.0047417,0.06047511,0.003803971,0.4306134,0.06545798,0.2539081],"study_design_scores_gemma":[0.001170472,0.0006930431,0.735766,0.001001613,0.001311047,0.0005669058,0.009684451,0.06351852,0.005091755,0.01599791,0.1645565,0.0006417803],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7022483,0.01774943,0.008212854,0.01635211,0.0002504966,0.001214909,0.008117628,0.0004452405,0.2454091],"genre_scores_gemma":[0.9839424,0.003753756,0.003710855,0.0007273199,0.0000260588,0.00008061703,0.001084771,0.00003344695,0.006640822],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.164503,"threshold_uncertainty_score":0.9690582,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2889860594","doi":"10.1177/1741134318799385","title":"Establishing healthy pharmaceutical regulations on statutory exclusivity: Lessons from the experience in the European Union, Canada, South Korea, Australia, and the United States","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Statutory law; Legislation; European union; Business; International trade; Constructive; Law; Political science; Process (computing)","authors":[{"name":"Kyung‐Bok Son","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1891385280060947,"gpt":0.3593994757691941,"spread":0.1702609477630994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09046639,0.0004872992,0.0006570952,0.003797252,0.01271983,0.01624173,0.002922365,0.005387324,0.00221049],"category_scores_gemma":[0.08158273,0.0006167146,0.00075997,0.006729988,0.02566129,0.01026003,0.005426907,0.008460934,0.0001912038],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.08497024,"about_ca_system_score_gemma":0.266249,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8017123,"about_ca_topic_score_gemma":0.8375875,"domain_scores_codex":[0.9576298,0.01673555,0.00344707,0.002896311,0.01380256,0.005488728],"domain_scores_gemma":[0.8158301,0.1051719,0.007273004,0.005684547,0.05897279,0.007067651],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.00008032133,0.0001932489,0.01453141,0.001483307,0.00005292805,0.00242778,0.1674492,0.001611056,0.001202675,0.5490389,0.03457644,0.2273527],"study_design_scores_gemma":[0.00003862783,0.0001912265,0.03125635,0.008863275,0.00008144078,0.0007541662,0.1600613,0.0008280004,0.002331196,0.03941244,0.7559006,0.0002814163],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"other","genre_gemma":"other","genre_scores_codex":[0.2146824,0.1247289,0.01637758,0.2976601,0.00188125,0.0006756363,0.000309686,0.0001499121,0.3435346],"genre_scores_gemma":[0.8650907,0.05150201,0.01616667,0.0504144,0.0003170683,0.0001444505,0.00021145,0.0001174802,0.01603572],"genre_candidate":"other","genre_consensus":"other","teacher_disagreement_score":0.1982877,"threshold_uncertainty_score":0.6165051,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2530530268","doi":"10.1177/1741134316673227","title":"Physicians’ loyalty to branded medicines in low-middle-income countries: A structural equation modeling","year":2016,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Manitoba","funders":"","keywords":"Loyalty; Structural equation modeling; Medical prescription; Marketing; Brand loyalty; Psychology; Health care; Affect (linguistics); Business; Medicine; Family medicine; Nursing; Political science","authors":[{"name":"Gholamhossein Mehralian","is_ca":false},{"name":"Zahra Sharif","is_ca":false},{"name":"Nazila Yousefi","is_ca":false},{"name":"Mahdi Akhgari","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3567624069152197,"gpt":0.4815236557034066,"spread":0.1247612487881869,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005400275,0.0006523159,0.0009607706,0.001768409,0.001200949,0.001999658,0.001269495,0.001594617,0.004735762],"category_scores_gemma":[0.008410536,0.00076739,0.002478104,0.001774673,0.0006814058,0.0009852387,0.001602797,0.001897071,0.0004409035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001625495,"about_ca_system_score_gemma":0.002253737,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.04924261,"about_ca_topic_score_gemma":0.02905239,"domain_scores_codex":[0.9973691,0.00161835,0.000138297,0.000293477,0.0001649714,0.0004158058],"domain_scores_gemma":[0.991222,0.006687896,0.001006675,0.0002520231,0.0004573011,0.0003741549],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00023817,0.001160794,0.9560419,0.00009700438,0.0007142419,0.0004735077,0.001946073,0.02649077,0.0001401793,0.002401527,0.001697071,0.008598703],"study_design_scores_gemma":[0.0002137694,0.001246931,0.393226,0.0003808457,0.0008366139,0.0002970148,0.006253889,0.5917742,0.0002138555,0.003440931,0.002030382,0.00008557788],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953514,0.0002468831,0.002288033,0.000716547,0.00002489237,0.00005230776,0.0003907787,0.00002056011,0.0009085314],"genre_scores_gemma":[0.997686,0.0001685196,0.001185918,0.00008025496,0.00001350505,0.00005404655,0.0004174732,0.000003615341,0.0003905997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04924261,"threshold_uncertainty_score":0.09791195,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2322087671","doi":"10.1177/1741134314545250","title":"Selection of the comparator product in the World Health Organisation Prequalification of Medicines Programme","year":2013,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Health Canada","funders":"","keywords":"Bioequivalence; Medicine; Product (mathematics); Innovator; Quality (philosophy); Pharmacology; Business","authors":[{"name":"Jan Welink","is_ca":false},{"name":"John Gordon","is_ca":true},{"name":"Matthias Stahl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1469357988361522,"gpt":0.3354100469351834,"spread":0.1884742480990313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01453096,0.0006606879,0.001271709,0.001491151,0.0007711352,0.002087437,0.001340957,0.003156898,0.02854115],"category_scores_gemma":[0.02448789,0.0003818545,0.001372954,0.0009096152,0.0009656064,0.001185922,0.0010743,0.001656528,0.01153568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009212128,"about_ca_system_score_gemma":0.00242258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005324366,"about_ca_topic_score_gemma":0.0006589275,"domain_scores_codex":[0.987817,0.004870384,0.002016018,0.0009902504,0.003850345,0.0004561018],"domain_scores_gemma":[0.9947648,0.001310994,0.0009421562,0.0006185361,0.0019285,0.0004349601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.02366486,0.003501007,0.006390546,0.01054147,0.0002272506,0.001085348,0.0008761775,0.000492378,0.06907533,0.01298269,0.0812214,0.7899415],"study_design_scores_gemma":[0.004043709,0.01628359,0.01443969,0.005071798,0.0005565154,0.001636582,0.000382982,0.0008680821,0.05895494,0.003219416,0.8943242,0.0002184233],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.1670866,0.05274569,0.1140772,0.01904134,0.01732419,0.1696986,0.024158,0.002290178,0.4335783],"genre_scores_gemma":[0.4496945,0.02014801,0.3016356,0.02511995,0.00231939,0.08006495,0.02287404,0.00114896,0.09699468],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02854115,"threshold_uncertainty_score":0.09547967,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4312203309","doi":"10.1177/17411343221146094","title":"Abbreviated new drug submission approval process: An overview","year":2022,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Bioequivalence; Innovator; Generic drug; Brand names; Product (mathematics); Drug; Business; Medical prescription; Prescription drug; Pharmacology; Marketing; Medicine; Mathematics; Finance; Pharmacokinetics","authors":[{"name":"Sonali S Amrutkar","is_ca":false},{"name":"Sanjay B. Patil","is_ca":false},{"name":"Atish S. Mundada","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1741468686271706,"gpt":0.3440508558626171,"spread":0.1699039872354466,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.06568383,0.00161929,0.001511129,0.006980517,0.002371446,0.01224024,0.004221736,0.005917929,0.03568536],"category_scores_gemma":[0.08363484,0.001776859,0.002393284,0.01013704,0.002818408,0.009674771,0.004185536,0.005140435,0.05392727],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009646417,"about_ca_system_score_gemma":0.03006934,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01034112,"about_ca_topic_score_gemma":0.009229113,"domain_scores_codex":[0.9253002,0.02503737,0.01243476,0.004223537,0.03004235,0.002961768],"domain_scores_gemma":[0.8818678,0.03379137,0.01720546,0.012367,0.05027689,0.004491404],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003283056,0.0002601492,0.002069923,0.00385783,0.00006924192,0.0004047697,0.0002692162,0.002237921,0.001387462,0.101059,0.3871306,0.5009255],"study_design_scores_gemma":[0.0000418175,0.0001857685,0.00377091,0.0007102362,0.00003019131,0.000721101,0.00005918528,0.0009636026,0.0006029723,0.006596906,0.9862508,0.00006655527],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"review","genre_scores_codex":[0.005993269,0.1715181,0.2377299,0.06094881,0.01138001,0.0159563,0.01570462,0.01180349,0.4689654],"genre_scores_gemma":[0.08677093,0.2442447,0.3062327,0.05493202,0.01819601,0.01818673,0.02036537,0.004386913,0.2466846],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.06568383,"threshold_uncertainty_score":0.3473735,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016416029","doi":"10.1177/1741134320918339","title":"A Novel Development and Portfolio Management Strategy for Generic Small Molecule Drug Products: Watergile ANDA","year":2020,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Apotex (Canada)","funders":"","keywords":"Portfolio; Business; New product development; Commercialization; Project portfolio management; Drug development; Product (mathematics); Process (computing); Risk analysis (engineering); Process management; Marketing; Industrial organization; Drug; Economics; Computer science; Finance; Project management; Pharmacology; Medicine; Management","authors":[{"name":"Sandra Tomassini","is_ca":true},{"name":"Ajay Babu Pazhayattil","is_ca":false},{"name":"Marzena Ingram","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1379154726627415,"gpt":0.2835873039882082,"spread":0.1456718313254667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01468457,0.0009309727,0.0009449809,0.004228824,0.001574669,0.00948187,0.002190457,0.002893831,0.008659621],"category_scores_gemma":[0.02175521,0.000596594,0.001029283,0.002208644,0.001716053,0.01045645,0.007282763,0.002044501,0.001732744],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004035988,"about_ca_system_score_gemma":0.009103154,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003026664,"about_ca_topic_score_gemma":0.003145399,"domain_scores_codex":[0.9910231,0.00400846,0.0004262871,0.001182775,0.00280657,0.0005529097],"domain_scores_gemma":[0.9933915,0.001953856,0.000916285,0.0009293605,0.001952819,0.0008562458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001783409,0.0004446559,0.004887461,0.0001946463,0.00013234,0.0005648199,0.0006114263,0.02066775,0.002137974,0.4184147,0.03091267,0.5208532],"study_design_scores_gemma":[0.0002153931,0.0006287453,0.003605292,0.0003930602,0.000115077,0.0007027206,0.000931868,0.266308,0.004237479,0.507252,0.2154287,0.0001815881],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"empirical","genre_scores_codex":[0.03065785,0.002078908,0.8241394,0.03725732,0.0003751472,0.001336699,0.0003323873,0.001595605,0.1022266],"genre_scores_gemma":[0.4261324,0.001535057,0.5318148,0.004807836,0.0004624357,0.0008158793,0.0004603789,0.000181978,0.0337892],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01468457,"threshold_uncertainty_score":0.07766038,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4408631771","doi":"10.1177/17411343251327092","title":"An assessment of Canada’s revised Patented Medicines (Notice of Compliance) Regulations","year":2025,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Calgary","funders":"Association canadienne du médicament générique","keywords":"Notice; Compliance (psychology); Business; Law; Medicine; Accounting; Political science; Psychology","authors":[{"name":"Aidan Hollis","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1459730021251669,"gpt":0.3173657869268764,"spread":0.1713927848017095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02957107,0.0007291842,0.0006602851,0.009405078,0.005895482,0.01241871,0.00562919,0.008708041,0.004610399],"category_scores_gemma":[0.07671024,0.00086071,0.001893218,0.006512298,0.002952244,0.001778349,0.001783273,0.004813271,0.0006446516],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1426258,"about_ca_system_score_gemma":0.3598967,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9764954,"about_ca_topic_score_gemma":0.9779127,"domain_scores_codex":[0.8699204,0.004819239,0.003679244,0.001749853,0.1087501,0.01108116],"domain_scores_gemma":[0.8760793,0.02061602,0.006172966,0.001992616,0.08808883,0.007050257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004274521,0.0005245777,0.04832371,0.001681907,0.0002381023,0.001713899,0.003865205,0.007907699,0.005835889,0.2430243,0.5569806,0.1294767],"study_design_scores_gemma":[0.0001430456,0.0003661485,0.1582399,0.0007295439,0.0002006912,0.0002736429,0.001365691,0.003040153,0.00199206,0.002869556,0.8304433,0.0003362577],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.1353079,0.01498483,0.005798341,0.2072242,0.003448331,0.003615042,0.01862843,0.001594324,0.6093985],"genre_scores_gemma":[0.7014683,0.009559419,0.01795186,0.09994178,0.001212426,0.0007802427,0.009872184,0.0002631955,0.1589506],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8573742,"threshold_uncertainty_score":0.9944325,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3163186261","doi":"10.1177/17411343211001424","title":"Does regulatory chill still concern states?","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"International Arbitration and Investment Law","field":"Business, Management and Accounting","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Legislature; Government (linguistics); Arbitration; Law and economics; State (computer science); Investment (military); Argument (complex analysis); Treaty; Law; Business; Political science; Economics; Politics; Medicine","authors":[{"name":"Zeleke Temesgen Boru","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03682751212411405,"gpt":0.2616703558542059,"spread":0.2248428437300918,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01419119,0.0003985429,0.0007757361,0.0009103457,0.007382677,0.02040618,0.002009544,0.02500466,0.01337922],"category_scores_gemma":[0.03110063,0.0004284063,0.001140938,0.001617799,0.01910532,0.02099023,0.004701696,0.02443174,0.002034408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007229922,"about_ca_system_score_gemma":0.01068098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01750691,"about_ca_topic_score_gemma":0.01316805,"domain_scores_codex":[0.985664,0.005160374,0.0004919379,0.002508247,0.00291999,0.003255349],"domain_scores_gemma":[0.9793624,0.01435059,0.001639165,0.001236219,0.002302599,0.001108998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.00000787774,0.00001287221,0.0005962615,0.00004772601,0.000007079578,0.0001881246,0.002334044,0.0001147004,0.00007329648,0.968983,0.02055922,0.007075789],"study_design_scores_gemma":[0.00001792008,0.00005418579,0.001321927,0.0007451474,0.00003201239,0.0004421278,0.00682434,0.000486599,0.0005152293,0.4871163,0.5023737,0.00007054574],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.01257282,0.008464484,0.005092834,0.7270801,0.002787208,0.00003270771,0.00006788502,0.0000688677,0.2438331],"genre_scores_gemma":[0.4721254,0.008257176,0.001471622,0.4730814,0.00371639,0.0001162805,0.00006928228,0.00009357029,0.04106886],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.02500466,"threshold_uncertainty_score":0.07505113,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3183715790","doi":"10.1177/17411343211035168","title":"Brand drug companies impeding generic drug company access to product samples: Estimated prevalence and impact on drug costs","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Toronto","funders":"Association canadienne du médicament générique","keywords":"Generic drug; Drug; Business; Market share; Brand names; Product (mathematics); Drug development; Marketing; Competition (biology); Order (exchange); Medicine; Pharmacology; Finance","authors":[{"name":"Paul Grootendorst","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1349456913073234,"gpt":0.3561349865959504,"spread":0.221189295288627,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004700759,0.0004167932,0.0005802014,0.005343196,0.0006131367,0.002421475,0.001235025,0.0007942186,0.00376196],"category_scores_gemma":[0.03194216,0.0006219943,0.001496519,0.006306533,0.001254094,0.001438247,0.001889626,0.001472513,0.0003410223],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008933621,"about_ca_system_score_gemma":0.004494062,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.4149305,"about_ca_topic_score_gemma":0.3823254,"domain_scores_codex":[0.9945713,0.001148601,0.0005657194,0.0005659084,0.001977424,0.001171025],"domain_scores_gemma":[0.9544656,0.01532245,0.02370882,0.001246588,0.003596913,0.001659588],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00008962649,0.00005127181,0.9903225,0.0001060558,0.0001821204,0.0001059454,0.0001396678,0.001340521,0.00003869635,0.0007637114,0.0006252407,0.006234583],"study_design_scores_gemma":[0.00001318012,0.00005363708,0.9921557,0.0001053396,0.0002137543,0.0002616281,0.0006738012,0.004431961,0.0001860419,0.0002865511,0.001602942,0.00001535098],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9797346,0.003928719,0.001282316,0.0007249627,0.00001221638,0.0002268228,0.009666465,0.00002459197,0.004399288],"genre_scores_gemma":[0.9916974,0.002165059,0.0006850102,0.00008769075,0.00002042883,0.00004672186,0.004332291,0.000007982319,0.0009573263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4149305,"threshold_uncertainty_score":0.8250307,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1978784436","doi":"10.1057/palgrave.jgm.4940034","title":"Editorial: Canada First to Pass Legislation on Delivering Generic Medicines to Developing Countries","year":2004,"lang":"en","type":"editorial","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Legislation; Business; Developing country; Medicine; International trade; Political science; Law; Economic growth; Economics","authors":[{"name":"Jim Keon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05232429836977266,"gpt":0.2877537100870722,"spread":0.2354294117172995,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009905716,0.005143512,0.006460817,0.00714834,0.008347272,0.01111745,0.006181672,0.03555974,0.01255644],"category_scores_gemma":[0.04340519,0.001752889,0.004221659,0.004211202,0.004692346,0.003732229,0.001449421,0.0357657,0.007345322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01756153,"about_ca_system_score_gemma":0.02131322,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.07592956,"about_ca_topic_score_gemma":0.1951146,"domain_scores_codex":[0.9910002,0.0008848622,0.0008710988,0.0008229402,0.005421218,0.0009996031],"domain_scores_gemma":[0.9565405,0.01150693,0.002120863,0.0009799841,0.02359276,0.005259008],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001796258,0.000007911124,0.00001460865,0.00005802319,0.00001231236,0.00005864363,0.000006702082,0.00001505625,0.00001524689,0.00008393482,0.9988367,0.0008729726],"study_design_scores_gemma":[0.0001051927,0.00002927751,0.0006280259,0.000510041,0.0001546466,0.0001482084,0.00008852289,0.0002053418,0.0001422819,0.0006169995,0.9973346,0.00003693701],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.00004573335,0.003249288,0.00006521267,0.07524093,0.9191386,0.00004086598,0.0001161397,0.00004402972,0.002059253],"genre_scores_gemma":[0.001068949,0.004583724,0.0001961468,0.07686239,0.8913583,0.0000576451,0.00009427349,0.00007782954,0.02570064],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.9240704,"threshold_uncertainty_score":0.1509752,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989800361","doi":"10.1177/1741134319886627","title":"The test data provision of USMCA: A potential to promote or negate the timely access to genetically engineered biologics?","year":2019,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Intellectual property; TRIPS architecture; TRIPS Agreement; International trade; Test (biology); Trade agreement; Treaty; Business; Human rights; Law; Law and economics; Political science; Economics; Free trade; Engineering","authors":[{"name":"Zeleke Temesgen Boru","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1659755085780909,"gpt":0.2935024081615318,"spread":0.1275268995834409,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04300812,0.0005744628,0.0009979935,0.002103857,0.004681629,0.01737889,0.006305024,0.01712014,0.01103132],"category_scores_gemma":[0.0853807,0.0008194455,0.001504611,0.002797649,0.01605947,0.01540835,0.007680197,0.01766936,0.002972091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01224617,"about_ca_system_score_gemma":0.04296139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.06299061,"about_ca_topic_score_gemma":0.05980809,"domain_scores_codex":[0.9547933,0.01086138,0.001780582,0.005335588,0.02328373,0.003945311],"domain_scores_gemma":[0.8920677,0.05551888,0.01000235,0.01345203,0.02464159,0.004317362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.00005735151,0.00004986018,0.0029712,0.0002254163,0.00003105867,0.0006536086,0.001281568,0.0003656924,0.001130721,0.882127,0.07061677,0.04048973],"study_design_scores_gemma":[0.00003209743,0.00009457065,0.00198459,0.001188327,0.00005490204,0.001318182,0.001291869,0.0008664377,0.003334037,0.1022202,0.8875132,0.0001015106],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.0275392,0.01528154,0.02985153,0.6196792,0.00475864,0.0002381163,0.001535964,0.0006780182,0.3004379],"genre_scores_gemma":[0.4341333,0.01693543,0.03921637,0.4276285,0.004218278,0.0005846028,0.001784179,0.0006098232,0.07488959],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.06299061,"threshold_uncertainty_score":0.2274514,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1990933841","doi":"10.1057/jgm.2008.1","title":"Climate of Change Continues in Canada","year":2008,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Liberian dollar; Market share; Business; Brand names; Generic drug; Reimbursement; Value (mathematics); Marketing; Industrial organization; Economics; Finance; Health care; Economic growth; Drug","authors":[{"name":"Jim Keon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1925670149164618,"gpt":0.2973795869913426,"spread":0.1048125720748808,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001351368,0.0003224577,0.0005699263,0.001632918,0.01335316,0.009813722,0.001275323,0.00253895,0.01513151],"category_scores_gemma":[0.003896529,0.0002163173,0.0006574393,0.005056116,0.005682578,0.002529589,0.003460068,0.003243897,0.0007411329],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.1089053,"about_ca_system_score_gemma":0.1764028,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.9830702,"about_ca_topic_score_gemma":0.9885167,"domain_scores_codex":[0.9961841,0.0001757729,0.00007142105,0.0002406301,0.00157667,0.001751495],"domain_scores_gemma":[0.9964101,0.0001738394,0.0003064531,0.00008219806,0.001735247,0.001292131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002053566,0.0001012815,0.06433814,0.0008918339,0.0001352259,0.002579896,0.02061883,0.003751874,0.001425069,0.2607273,0.5504513,0.09477388],"study_design_scores_gemma":[0.00001211429,0.00001579662,0.066742,0.0001945939,0.00001757484,0.0001424023,0.01488651,0.000516855,0.0001314639,0.008766937,0.9084929,0.00008088382],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.1288463,0.01964258,0.001308788,0.4419063,0.005125615,0.0001147589,0.007349986,0.0004123257,0.3952933],"genre_scores_gemma":[0.8823293,0.01732635,0.001081319,0.04693059,0.001075733,0.00005829226,0.001900778,0.0001899861,0.04910766],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.1089053,"threshold_uncertainty_score":0.7901672,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1993877811","doi":"10.1177/1741134312445867","title":"<i>Sanofi-Aventis et al. v. Apotex Inc. et al.</i> : The one hundred eight million dollar question","year":2012,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Damages; Settlement (finance); Liberian dollar; Denial; Law; Business; Political science; Finance; Psychology","authors":[{"name":"Frederick H. Rein","is_ca":false},{"name":"Joseph B. Crystal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1229180066764499,"gpt":0.2803149431935992,"spread":0.1573969365171493,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005470712,0.0008504482,0.0006734681,0.00123801,0.008381238,0.01066801,0.00299264,0.03394611,0.01030119],"category_scores_gemma":[0.01321874,0.00098623,0.001354229,0.001653954,0.004308966,0.004334285,0.002090775,0.01407184,0.004590622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00838655,"about_ca_system_score_gemma":0.01151171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.09074227,"about_ca_topic_score_gemma":0.1708734,"domain_scores_codex":[0.9931426,0.0008970181,0.0004055788,0.0008187505,0.002681202,0.002054824],"domain_scores_gemma":[0.9945835,0.003381956,0.0005196162,0.0002236089,0.0009769833,0.0003142754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006500039,0.00004436456,0.001182796,0.00008706345,0.00002050218,0.0004170891,0.0008496804,0.0001312278,0.0004962707,0.2680433,0.7239186,0.004744223],"study_design_scores_gemma":[0.0001611283,0.0001190491,0.01028706,0.0006565147,0.00009349121,0.0004779447,0.001597887,0.0006981195,0.001394206,0.05196622,0.9323534,0.0001949533],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"empirical","genre_scores_codex":[0.01482404,0.008027591,0.001647506,0.4459597,0.004437952,0.0001874444,0.002535945,0.0003276714,0.5220521],"genre_scores_gemma":[0.1274883,0.003318775,0.001350554,0.7548515,0.002770005,0.0003923553,0.0006827798,0.00007695963,0.1090688],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.09074227,"threshold_uncertainty_score":0.1804281,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3173567414","doi":"10.1177/17411343211008589","title":"The anatomy of CUSMA’s patent: Does it still reflect an equipoise?","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"TRIPS architecture; TRIPS Agreement; Intellectual property; Biosimilar; Access to medicines; Patent troll; Term (time); Business; Law and economics; Patent Act; Patent infringement; Protocol (science); International trade; Law; Patent law; Political science; Medicine; Economics; Engineering; Alternative medicine","authors":[{"name":"Zeleke Temesgen Boru","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1779393943499631,"gpt":0.3030065297278441,"spread":0.1250671353778809,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00896796,0.0005667428,0.0005930807,0.002230635,0.007285255,0.01284292,0.002006371,0.01120071,0.01625561],"category_scores_gemma":[0.02544167,0.000499666,0.0006148237,0.001827798,0.03018382,0.02230647,0.003937392,0.016018,0.003240656],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007515652,"about_ca_system_score_gemma":0.01000054,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01436937,"about_ca_topic_score_gemma":0.00926305,"domain_scores_codex":[0.9925066,0.002683761,0.000294275,0.001437249,0.002220754,0.0008574282],"domain_scores_gemma":[0.9920682,0.005299584,0.0003717693,0.000898038,0.001038122,0.0003242496],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000003788672,0.000002243117,0.00002756576,0.00001234846,0.000001000028,0.00003950896,0.0005173873,0.00002519672,0.00003311903,0.9876654,0.006749643,0.00492262],"study_design_scores_gemma":[0.00001218426,0.00003714014,0.0002976522,0.0002115023,0.000008655158,0.0002811618,0.0007648531,0.0004354036,0.0002076103,0.5166422,0.4810656,0.0000360294],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"other","genre_gemma":"commentary","genre_scores_codex":[0.008970676,0.01613748,0.03889084,0.2233857,0.006859838,0.0001471859,0.0001936591,0.0003034558,0.7051111],"genre_scores_gemma":[0.5906371,0.01691998,0.03373821,0.08117002,0.00971581,0.0006899144,0.0002188033,0.0005261118,0.2663841],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.01625561,"threshold_uncertainty_score":0.05453014,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3196294283","doi":"10.1177/17411343211029995","title":"Comparison of generic drug registration strategies between health Canada and Gulf Cooperation Council","year":2021,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Innovator; Product (mathematics); Health care; Business; Quality (philosophy); Political science; Finance; Law","authors":[{"name":"Narayana R Charyulu","is_ca":false},{"name":"Anoop Narayanan Vadakkepushpakath","is_ca":false},{"name":"Amitha Shetty","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1915405483728022,"gpt":0.3392887336589849,"spread":0.1477481852861827,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006569428,0.0003190518,0.0004198276,0.00515965,0.002597983,0.00465376,0.001434132,0.0009441043,0.006468657],"category_scores_gemma":[0.01812949,0.000261356,0.0008524931,0.007763945,0.001175232,0.001046025,0.001586706,0.001039723,0.0007430381],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.05997039,"about_ca_system_score_gemma":0.111649,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.928651,"about_ca_topic_score_gemma":0.9440965,"domain_scores_codex":[0.9886363,0.001416517,0.0004675666,0.000604604,0.005592302,0.003282736],"domain_scores_gemma":[0.9839536,0.00243731,0.001586116,0.0004156982,0.008698087,0.002909229],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.003590122,0.0007843312,0.3330777,0.002061025,0.0004577193,0.001342592,0.005597112,0.00816925,0.002615221,0.1028869,0.1399508,0.3994674],"study_design_scores_gemma":[0.0005147316,0.0008535694,0.7451554,0.000691086,0.0004084003,0.0007819918,0.01303163,0.008541333,0.002745161,0.002097048,0.2249549,0.000224717],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6887088,0.01841532,0.002200147,0.01927236,0.0002652939,0.001148819,0.009924563,0.000286657,0.2597781],"genre_scores_gemma":[0.9668046,0.005186547,0.001739467,0.002354346,0.00005056245,0.0001107206,0.004588134,0.00005102739,0.01911456],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9400296,"threshold_uncertainty_score":0.4351177,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905138060","doi":"10.1177/1741134318810061","title":"Tough medicine: Ensuring access to affordable drugs requires fixing trade agreements starting with NAFTA","year":2018,"lang":"en","type":"article","venue":"Journal of Generic Medicines The Business Journal for the Generic Medicines Sector","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Intellectual property; International trade; General partnership; Negotiation; Market access; Business; Biosimilar; International trade law; Modernization theory; Subsidy; Balance (ability); International economics; Economics; Law; Economic growth; Political science; Finance; Medicine; Market economy","authors":[{"name":"María Fabiana Jorge","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1407296790207842,"gpt":0.3383205404430396,"spread":0.1975908614222554,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02306386,0.0007924964,0.0008303635,0.001767122,0.006717279,0.01305057,0.001833106,0.01573881,0.01573075],"category_scores_gemma":[0.05002005,0.0004852633,0.001406202,0.001142818,0.0104145,0.01725447,0.005477391,0.01279816,0.002727866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.007889775,"about_ca_system_score_gemma":0.01657273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01947177,"about_ca_topic_score_gemma":0.01291046,"domain_scores_codex":[0.9837831,0.004942527,0.00094106,0.002254156,0.005696371,0.002382929],"domain_scores_gemma":[0.9834246,0.00714643,0.002030182,0.001888775,0.004030735,0.001479393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008799649,0.00005213719,0.0009728831,0.000171462,0.00003362762,0.0002684905,0.001494421,0.0003132925,0.0009474198,0.9226961,0.041311,0.03165112],"study_design_scores_gemma":[0.00005363518,0.0001364133,0.002086704,0.0009502653,0.00004149407,0.0002557181,0.001377175,0.0006048079,0.0009742769,0.3517604,0.6416611,0.00009806627],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.03400974,0.01399695,0.02934477,0.5695885,0.009832356,0.0002696822,0.0003675854,0.0004333649,0.342157],"genre_scores_gemma":[0.6081378,0.008631155,0.05626176,0.24212,0.003680923,0.0005972048,0.0004286345,0.0002543509,0.07988822],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.02306386,"threshold_uncertainty_score":0.1219748,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}